TENAX THERAPEUTICS, INC. (TENX) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$18.78M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$16.57M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$16.81M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$11.79M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$18.78M | (m) | $0.00* | (m) | (m) | -$14.15M* | (m) | $12.85M | $5.93M | (m) |
| 2026-03-31 | Reported | (m) | -$16.57M | (m) | $0.00 | (m) | (m) | -$9.31M | (m) | $11.54M | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$16.81M | (m) | $0.00* | (m) | (m) | -$9.15M* | (m) | $10.33M | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$11.79M | (m) | $0.00* | (m) | (m) | -$6.26M* | (m) | $6.12M | $5.67M | (m) |
| 2025-03-31 | Reported | (m) | -$11.34M | (m) | $0.00 | (m) | (m) | -$6.97M | (m) | $5.68M | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$4.62M | (m) | (m) | (m) | (m) | -$3.09M* | (m) | $3.11M | (m) | (m) |
| 2024-06-30 | Reported | (m) | -$3.67M | (m) | (m) | (m) | (m) | -$3.03M* | (m) | $2.33M | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$3.91M | (m) | (m) | (m) | (m) | -$5.17M | (m) | $2.68M | (m) | (m) |
| 2023-09-30 | Reported | (m) | $2.12M | (m) | (m) | (m) | (m) | -$2.08M* | (m) | $1.07M | (m) | (m) |
| 2023-06-30 | Reported | (m) | $1.24M | (m) | (m) | (m) | $1.60K* | -$922.97K* | (m) | $197.90K | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$1.54M | (m) | (m) | (m) | $1.24K | -$1.72M | (m) | $265.74K | (m) | (m) |
| 2022-09-30 | Reported | (m) | $2.92M | (m) | (m) | (m) | $0.00* | -$3.33M* | (m) | $1.54M | (m) | (m) |
| 2022-06-30 | Reported | (m) | $2.86M | (m) | (m) | (m) | $0.00* | -$3.43M* | (m) | $1.52M | (m) | (m) |
| 2022-03-31 | Reported | (m) | $2.72M | (m) | (m) | (m) | $6.32K | -$2.94M | (m) | $1.18M | (m) | (m) |
| 2021-09-30 | Reported | (m) | $3.80M | (m) | (m) | (m) | $1.68K* | -$3.02M* | (m) | $1.16M | $2.64M | (m) |
| 2021-06-30 | Reported | (m) | $1.96M | (m) | (m) | (m) | $1.88K* | -$1.85M* | (m) | $693.22K | $1.27M | (m) |
| 2021-03-31 | Reported | (m) | $23.75M | (m) | (m) | (m) | $0.00 | -$3.22M | (m) | $22.38M | -$1.37M | (m) |
| 2020-09-30 | Reported | (m) | $2.23M | (m) | (m) | (m) | $0.00* | -$2.39M* | (m) | $1.05M | $1.17M | (m) |
| 2020-06-30 | Reported | (m) | $2.14M | (m) | (m) | (m) | $0.00* | -$2.23M* | (m) | $1.27M | $869.21K | (m) |
| 2020-03-31 | Reported | (m) | $2.67M | (m) | (m) | (m) | $0.00 | -$2.67M | (m) | -$1.34M | -$1.32M | (m) |
| 2019-09-30 | Reported | (m) | $2.26M | (m) | (m) | (m) | $0.00* | -$1.78M* | (m) | -$916.98K | -$1.34M | (m) |
| 2019-06-30 | Reported | (m) | $1.82M | (m) | (m) | (m) | $0.00* | -$1.91M* | (m) | -$649.25K | -$1.17M | (m) |
| 2019-03-31 | Reported | (m) | $1.66M | (m) | (m) | (m) | $3.57K | -$2.13M | (m) | -$482.77K | -$1.18M | (m) |
| 2018-09-30 | Reported | (m) | $1.55M | (m) | (m) | (m) | $0.00* | -$1.56M* | (m) | -$362.63K | -$1.19M | (m) |
| 2018-06-30 | Reported | (m) | $1.89M | (m) | (m) | (m) | $2.70K* | -$1.19M* | (m) | -$311.15K | -$1.58M | (m) |
| 2018-03-31 | Reported | (m) | $1.22M | (m) | (m) | (m) | $3.10K | -$1.56M | (m) | -$58.59K | -$1.16M | (m) |
| 2017-09-30 | Reported | (m) | $1.31M | (m) | (m) | (m) | $1.26K* | -$1.23M* | (m) | -$253.97K | -$1.06M | (m) |
| 2017-06-30 | Reported | (m) | $3.01M | (m) | (m) | (m) | $0.00* | -$5.60M* | (m) | -$1.22M | -$1.79M | (m) |
| 2017-03-31 | Reported | (m) | $3.50M | (m) | (m) | (m) | $3.27K | -$4.04M | (m) | -$2.05M | -$1.45M | (m) |
| 2016-09-30 | Reported | (m) | $4.50M | (m) | (m) | (m) | $0.00* | -$4.28M* | (m) | -$3.23M | -$1.27M | (m) |
| 2016-06-30 | Reported | (m) | $4.67M | (m) | (m) | (m) | $0.00* | -$5.17M* | (m) | -$3.43M | -$1.24M | (m) |
| 2016-03-31 | Reported | (m) | -$5.71M | (m) | (m) | (m) | $2.88K | -$3.32M | (m) | $3.94M | $1.76M | (m) |
| 2015-10-31 | Reported | (m) | -$3.75M | (m) | (m) | (m) | $0.00* | -$2.70M* | (m) | $2.52M | $1.23M | (m) |
| 2015-09-30 | Reported | (m) | -$3.10M | (m) | (m) | (m) | $16.69K* | -$3.13M* | (m) | $1.68M | $1.43M | (m) |
| 2015-07-31 | Reported | (m) | -$3.11M | (m) | (m) | (m) | $16.69K | -$3.84M | (m) | $1.75M | $1.37M | (m) |
| 2015-06-30 | Reported | (m) | -$4.87M | (m) | (m) | (m) | $0.00* | -$2.80M* | (m) | $1.95M | $1.93M | (m) |
| 2015-03-31 | Reported | (m) | -$3.20M | (m) | (m) | (m) | $0.00 | -$2.54M | (m) | $1.58M | $1.62M | (m) |
| 2015-01-31 | Reported | (m) | -$3.13M | (m) | (m) | (m) | $4.23K* | -$3.23M* | (m) | $1.23M | $1.91M | (m) |
| 2014-10-31 | Reported | (m) | -$4.14M | (m) | (m) | (m) | $0.00* | -$2.91M* | (m) | $2.56M | $1.59M | (m) |
| 2014-07-31 | Reported | (m) | -$2.42M | (m) | (m) | (m) | $0.00 | -$1.98M | (m) | $966.51K | $1.45M | (m) |
| 2014-01-31 | Reported | (m) | -$2.43M | (m) | (m) | (m) | $9.80K* | -$2.71M* | (m) | $689.67K | $1.78M | (m) |
| 2013-10-31 | Reported | (m) | -$2.11M | (m) | (m) | (m) | $0.00* | -$2.01M* | (m) | $748.57K | $1.42M | (m) |
| 2013-07-31 | Reported | (m) | -$1.59M | (m) | (m) | (m) | $0.00 | -$1.56M | (m) | $772.89K | $982.52K | (m) |
| 2013-01-31 | Reported | (m) | -$1.59M | (m) | (m) | (m) | $2.21K* | -$739.01K* | (m) | $369.45K | $1.44M | (m) |
| 2012-10-31 | Reported | (m) | -$682.84K | (m) | (m) | (m) | $0.00* | -$1.13M* | (m) | $604.57K | $422.84K | (m) |
| 2012-07-31 | Reported | (m) | -$1.68M | (m) | (m) | (m) | $12.72K | -$1.61M | (m) | $637.27K | $1.26M | (m) |
| 2012-01-31 | Reported | (m) | -$1.87M | (m) | (m) | (m) | $2.50K* | -$2.27M* | (m) | $599.93K | $1.42M | (m) |
| 2011-10-31 | Reported | (m) | -$2.05M | (m) | (m) | (m) | $8.87K* | -$2.53M* | (m) | $488.58K | $1.66M | (m) |
| 2011-07-31 | Reported | (m) | -$2.43M | (m) | (m) | (m) | $0.00 | -$2.05M | (m) | $651.96K | $1.80M | (m) |
| 2011-01-31 | Reported | (m) | $2.75M | (m) | (m) | (m) | $326.31K* | -$2.26M* | (m) | $498.52K | $2.28M | (m) |
| 2010-10-31 | Reported | (m) | $2.06M | (m) | (m) | (m) | -$49.89K* | -$1.78M* | (m) | $572.65K | $1.51M | (m) |
| 2010-07-31 | Reported | (m) | $3.02M | (m) | (m) | (m) | -$88.91K | -$2.61M | (m) | $1.15M | $1.88M | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$56.38M | (m) | $0.00 | (m) | (m) | -$35.80M | (m) | $32.67M | (m) | $0.00 |
| 2024-12-31 | Reported | (m) | -$19.49M | (m) | $0.00 | (m) | (m) | -$14.81M | (m) | $12.71M | (m) | $0.00 |
| 2023-12-31 | Reported | (m) | -$8.23M | (m) | (m) | (m) | (m) | -$5.90M | (m) | $3.23M | (m) | $0.00 |
| 2022-12-31 | Reported | (m) | $11.05M | (m) | (m) | (m) | $2.32K | -$11.39M | (m) | $5.38M | (m) | $0.00 |
| 2021-12-31 | Reported | (m) | -$32.73M | (m) | (m) | (m) | $5.25K | -$10.86M | (m) | $25.15M | $7.58M | $0.00 |
| 2020-12-31 | Reported | (m) | $9.87M | (m) | (m) | (m) | $3.49K | -$9.27M | (m) | $4.56M | $5.31M | $0.00 |
| 2019-12-31 | Reported | (m) | -$8.56M | (m) | (m) | (m) | $3.57K | -$7.56M | (m) | $3.47M | $5.08M | $0.00 |
| 2018-12-31 | Reported | (m) | -$6.89M | (m) | (m) | (m) | $7.59K | -$5.50M | (m) | $1.24M | $5.65M | $0.00 |
| 2017-12-31 | Reported | (m) | -$9.21M | (m) | (m) | (m) | $4.54K | -$12.14M | (m) | $3.53M | $5.68M | $0.00 |
| 2016-12-31 | Reported | (m) | -$52.65M | (m) | (m) | (m) | $2.88K | -$15.87M | (m) | $13.14M | $6.25M | -$7.96M |
| 2015-04-30 | Reported | (m) | -$14.82M | (m) | (m) | (m) | $4.23K | -$9.75M | (m) | $6.66M | $7.17M | $0.00 |
| 2014-04-30 | Reported | (m) | -$16.61M | (m) | (m) | (m) | $9.80K | -$9.26M | (m) | $3.00M | $13.77M | $0.00 |
| 2013-04-30 | Reported | (m) | -$5.19M | (m) | (m) | (m) | $17.20K | -$4.92M | (m) | $2.46M | $3.68M | (m) |
| 2012-04-30 | Reported | (m) | -$8.22M | (m) | (m) | (m) | $17.65K | -$8.28M | (m) | $2.46M | $6.09M | (m) |
| 2011-04-30 | Reported | (m) | $10.56M | (m) | (m) | (m) | $240.82K | -$8.40M | (m) | $2.68M | $7.68M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |